At the news
? BULLISHIMPACT 7/10 8-K filed May 14, 2026 at 07:01 ET
Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib in atopic dermatitis at the SID Annual Meeting, showing 75% EASI 75 achievement in the 8-week cohort and durable drug-free remissions with no rebound. The biomarker data supports the novel ITK inhibition mechanism, including persistent Treg induction and JAK-STAT pathway modulation. The company is enrolling a Phase 2 SIERRA1 trial (~200 patients) and its partner Angel Pharmaceuticals is enrolling a Phase 1b/2 trial in China.
- Phase 1 trial enrolled 72 patients with moderate-to-severe atopic dermatitis; 35% had prior systemic therapy
- Cohort 4 (200 mg BID, 8 weeks): 75% achieved EASI 75, 25% achieved EASI 90, 33% achieved IGA 0/1
- Cohort 3 (200 mg BID, 4 weeks): 50% achieved EASI 75, 8% achieved EASI 90, 25% achieved IGA 0/1
- No disease rebound observed during drug-free follow-up (30-90 days); no rescue medications required
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access